Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial

AimsDigital applications have the potential to enhance diabetes management, particularly in patients treated with insulin. This study aims to evaluate the impact of a digital application on self-management (ESYSTA, Germany), expressed in a change in HbA1c levels, in people with diabetes treated with...

Full description

Saved in:
Bibliographic Details
Main Authors: Lena Roth, Nico Steckhan, Peter E. H. Schwarz
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Digital Health
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fdgth.2025.1544668/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849426658853912576
author Lena Roth
Nico Steckhan
Peter E. H. Schwarz
author_facet Lena Roth
Nico Steckhan
Peter E. H. Schwarz
author_sort Lena Roth
collection DOAJ
description AimsDigital applications have the potential to enhance diabetes management, particularly in patients treated with insulin. This study aims to evaluate the impact of a digital application on self-management (ESYSTA, Germany), expressed in a change in HbA1c levels, in people with diabetes treated with insulin.Materials and methodsA randomized controlled, multicentric trial was conducted in 204 people with diabetes (60% type 2 diabetes) treated with insulin to assess the efficacy of ESYSTA. Participants were randomly assigned to either the intervention group (IG) using ESYSTA in addition to the German standard of Care (SoC) according to the German disease management programs (DMP) for 6 months or a control group (CG) receiving SoC only. The primary endpoint was the change in HbA1c levels. Secondary endpoints included well-being and diabetes-related distress.ResultsA clinically relevant reduction in HbA1c levels of on average −0.48% points (−0.66; −0.29) was observed in the IG after 6 months. Compared to the CG, this reduction was more pronounced, especially in the per-protocol sample [mean difference, −0.28% points; 95% CI (−0.54; −0.02)]. Improvements in the IG in further secondary endpoints, such as well-being or diabetes-related distress, indicate enhanced overall glycemic control and patient satisfaction in the IG.ConclusionsThe use of ESYSTA improved HbA1c levels and other secondary outcomes in people with diabetes who are treated with insulin in comparison with German SoC in the context of DMP. These findings support the integration of digital tools in routine diabetes care to optimize patient outcomes.Clinical Trial Registrationhttps://drks.de/search/de/trial/DRKS00025996, identifier DRKS00025996.
format Article
id doaj-art-862da64fd1e94b729fa939c4aae77f5b
institution Kabale University
issn 2673-253X
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Digital Health
spelling doaj-art-862da64fd1e94b729fa939c4aae77f5b2025-08-20T03:29:18ZengFrontiers Media S.A.Frontiers in Digital Health2673-253X2025-06-01710.3389/fdgth.2025.15446681544668Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trialLena RothNico SteckhanPeter E. H. SchwarzAimsDigital applications have the potential to enhance diabetes management, particularly in patients treated with insulin. This study aims to evaluate the impact of a digital application on self-management (ESYSTA, Germany), expressed in a change in HbA1c levels, in people with diabetes treated with insulin.Materials and methodsA randomized controlled, multicentric trial was conducted in 204 people with diabetes (60% type 2 diabetes) treated with insulin to assess the efficacy of ESYSTA. Participants were randomly assigned to either the intervention group (IG) using ESYSTA in addition to the German standard of Care (SoC) according to the German disease management programs (DMP) for 6 months or a control group (CG) receiving SoC only. The primary endpoint was the change in HbA1c levels. Secondary endpoints included well-being and diabetes-related distress.ResultsA clinically relevant reduction in HbA1c levels of on average −0.48% points (−0.66; −0.29) was observed in the IG after 6 months. Compared to the CG, this reduction was more pronounced, especially in the per-protocol sample [mean difference, −0.28% points; 95% CI (−0.54; −0.02)]. Improvements in the IG in further secondary endpoints, such as well-being or diabetes-related distress, indicate enhanced overall glycemic control and patient satisfaction in the IG.ConclusionsThe use of ESYSTA improved HbA1c levels and other secondary outcomes in people with diabetes who are treated with insulin in comparison with German SoC in the context of DMP. These findings support the integration of digital tools in routine diabetes care to optimize patient outcomes.Clinical Trial Registrationhttps://drks.de/search/de/trial/DRKS00025996, identifier DRKS00025996.https://www.frontiersin.org/articles/10.3389/fdgth.2025.1544668/fullglycemic controldigital health application (DiHA/DiGA)insulin-treated diabetes mellitusdiabetes care technologydiabetes self-managementblood glucose tracking
spellingShingle Lena Roth
Nico Steckhan
Peter E. H. Schwarz
Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial
Frontiers in Digital Health
glycemic control
digital health application (DiHA/DiGA)
insulin-treated diabetes mellitus
diabetes care technology
diabetes self-management
blood glucose tracking
title Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial
title_full Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial
title_fullStr Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial
title_full_unstemmed Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial
title_short Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial
title_sort impact of a digital application on hba1c levels in people with diabetes a randomized controlled trial
topic glycemic control
digital health application (DiHA/DiGA)
insulin-treated diabetes mellitus
diabetes care technology
diabetes self-management
blood glucose tracking
url https://www.frontiersin.org/articles/10.3389/fdgth.2025.1544668/full
work_keys_str_mv AT lenaroth impactofadigitalapplicationonhba1clevelsinpeoplewithdiabetesarandomizedcontrolledtrial
AT nicosteckhan impactofadigitalapplicationonhba1clevelsinpeoplewithdiabetesarandomizedcontrolledtrial
AT peterehschwarz impactofadigitalapplicationonhba1clevelsinpeoplewithdiabetesarandomizedcontrolledtrial